Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm
Pfizer is to pay US$81.50/shr for Medivation, considerably above Sanofi’s original offer of US$52.5bil. This values the Xtandi-originator at...
192 Views
JAPAN FLOW III: The Mechanics of BOJ Buying
This is the latest in a series of JAPAN FLOW regarding recent and forward flow dynamics of Japan equities.The first two are: JAPAN FLOW I: The...
326 Views
A 'heads Up' on Changing World Heights
A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...
164 Views
Death Rattle for Defensives?
While it is not a given that a switch from a high growth, high interest rate environment to a low growth, low interest rate environment is a good...
1k Views
Implications for Astellas as Medivation Invites Offers
Medivation appears to have finally given up hope of remaining independent and has invited tenders to be made by mid-August, with Sanofi, Pfizer,...
195 Views